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Lung cancer is the leading cause of cancer death worldwide. Therefore, advances in 
diagnosis and treatment of the disease are urgently needed. MicroRNAs (miRNAs) are 
a family of small non-encoding RNAs that regulate gene expression at the 
transcriptional level. MiRNAs have been reported to be deregulated and to play a 
critical role in different types of cancer, including lung cancer. Thus, miRNA profiling in 
lung cancer patients has become the core of several investigations. To this end, the 
development of a multitude of platforms for miRNA-profiling analysis has been 
essential. This review focuses on the different technologies available to assess miRNAs 
and the most important results obtained to date in lung cancer.  
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1. INTRODUCTION 
Lung cancer is the leading cause of cancer-related death worldwide [1]. The disease 
can be classified into two subgroups based on histology: Non-small cell lung cancer 
(NSCLC) (85%) and small cell lung cancer (SCLC) (15%) [2]. Five year survival remains 
poor (15%) [3], mainly because the tumor has already developed local or distant 
metastasis at the time of diagnosis [4]. Despite the existence of several distinct tumor 
phenotypes, therapeutic decisions are mainly based on clinical features such as stage 
or performance status. This highlights the need for new biomarkers which can be used 
in clinical practice, not only as diagnostic or/and prognostic tools but also as 
therapeutic targets. 
MicroRNAs (miRNAs) are a family of small, highly conserved non-encoding RNAs of 18-
25 nucleotides in length that were discovered in the early 1990s by Victor Ambros and 
colleagues in Caenorhabditis elegans [5]. Long primary transcripts (pri-miRNA) are 
transcribed by RNA polymerase II and then sequentially processed by the 
ribonucleases Drosha and Dicer [6] (Figure 1). MiRNAs are important regulators of 
genes related to fundamental processes such as cellular proliferation, differentiation, 
development or apoptosis. These small molecules regulate gene expression binding 
the 3’ region of target messenger RNA (mRNA), thereby inhibiting translation and 
promoting degradation of mRNA [7,8]. 
Altered miRNA profiles have been observed in virtually every tumor type when 
compared with normal cells or tissue. It appears they act on both oncogenes and 
tumor suppressor genes [9]. This phenomenon was first observed in chronic 
lymphocytic leukaemia (CLL), when Calin et al. demonstrated that the gene cluster 
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containing miR-15 and miR-16 was deleted in most CLL patients [10]. In lung cancer, 
miRNA expression patterns have been extensively studied and it has been proved that 
they are involved in both lung cancer development and progression [11]. Early on, 
studies pointed towards a relationship between lung cancer and miRNAs. A decade 
ago, Takamizawa et al. observed that reduced expression of let-7, a negative regulator 
of the RAS oncogene, was significantly associated with shortened survival in NSCLC 
patients [12]. More recently, overexpression of miR-221 and miR-222 has been 
associated with aggressive NSCLC due to their ability to enhance cellular migration by 
targeting PTEN [13]. Similarly, the miR-34 family has been related to tumor 
proliferation through the p53 pathway and relapse of NSCLC patients [14]. Some of the 
most relevant studies regarding the role of miRNAs in lung cancer are summarized in 
Table 1. 
There is growing evidence to indicate that miRNAs have adequate characteristics for a 
biomarker: i) they display unique expression profiles in different human cancers, ii) 
due to their resistance to ribonucleases, miRNAs are more stable than mRNAs, and iii) 
detection and quantification of miRNAs can be efficiently assessed by various 
platforms and matrices [15,16,17]. Presently, approaches such as microarrays, 
quantitative reverse transcriptase PCR (qRT-PCR), next generation sequencing (NGS) 
and in situ hybridization (ISH), (described in Table 2) have been used in order to 
analyze miRNA expression in lung cancer samples.  
We performed a comprehensive search of the literature using MEDLINE for original 
and review articles related to the terms “microRNAs”, “microRNAs detection” and 
“microRNAs and lung cancer” (last update January 2014). We also reviewed the 
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bibliographies reported in these articles to complete the search. Only articles 
published in English were included. The following sections give an overview of the 
different methods used for isolation, detection and quantification of miRNAs in various 
biological samples from lung cancer patients. This is not intended to be an exhaustive 
and detailed description of the methodological aspects of all these topics, which have 
been covered in several recent articles. Rather, the intention is to provide an updated 
overview regarding the value of different approaches in miRNA analysis in clinical 
specimens that can be used as tools for the identification of new biomarkers and 
therapeutic targets in lung cancer. In this regard, a summary of the most relevant 
miRNAs discussed in this review and their clinical implications in lung cancer is 
provided in Table 3 
2. MICRORNA ISOLATION AND PURIFICATION 
In general, the accuracy and reliability of different detection methods depend on the 
quality and abundance of miRNAs. Consequently, use of an appropriate RNA isolation 
method is important. High quality miRNA can be isolated from tissue, cells or blood 
using the same principles as for isolation of total RNA, with slight modifications. 
Commercially available reagents such as guanidinium thiocyanate and purification 
columns with silica-based membranes are generally used. It has also been documented 
that miRNA stability and integrity are preserved in formalin-fixed, paraffin-embedded 
(FFPE) tissues [16], and can be successfully isolated [18]. Since the technique for 
collection is non-invasive, peripheral blood has been widely used for miRNA isolation. 
Not only whole blood, but also serum and plasma samples have proved to be useful, 
mainly because of the high stability of miRNAs isolated from these sources. In fact, 
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tumors appear to release vesicular structures (exosomes), which have been proved to 
contain and protect miRNAs, into peripheral circulation [19]. Since these exosomes can 
be isolated from minimally invasive samples, and they contain stable miRNAs, they 
have been suggested as surrogate markers for biopsy profiling. 
During manipulation and isolation procedures it is pivotal to avoid the action of RNase 
enzymes that could partially or totally digest the purified miRNA fraction. 
Consequently, before proceeding with the analysis, it is recommended to assess the 
integrity of RNA extracted and therefore automated capillary electrophoresis are 
widely used for detecting the presence or absence of RNA degradation products. This 
method provides a RNA integrity number (RIN) which is calculated by a software 
algorithm and which depends on the entire electrophoretic trace of the RNA sample. 
Some authors have suggested that a minimal RIN of 7 should be exceed in order to 
obtain reliable miRNA-analysis results [20]. Due to low molecular weight and low 
abundance of miRNAs, which can limit the method’s sensitivity in some cases, small 
RNA (sRNA) enrichment step is recommended when using miRNA detection methods 
such as microarray platforms and NGS [21,22]. Different methods, such as ultra-fast 
denaturing polyacrylamide gel electrophoresis (PAGE) purification of nucleic acids 
followed by ethanol precipitation [23], or commercial kits that included silica-based 
column systems can be used for this purpose.  
3. MICRORNA DETECTION METHODS AND CLINICAL CORRELATES IN LUNG CANCER 
3.1. Analysis in biological specimens. 
3.1.1. Quantitative real-time PCR (qRT-PCR) 
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qRT-PCR technology is considered a “gold standard” in the quantification of gene 
expression. Some of its major advantages are speed, sensitivity and the low amount of 
RNA required. The first step when analysing miRNA by qRT-PCR is the conversion of 
RNA into complementary DNA (cDNA). Currently, two different approaches can be 
used for reverse transcription (RT) of miRNAs: miRNA universal RT or miRNA-specific 
RT. In universal RT, miRNAs are tailed with a common sequence and a universal PCR 
primer is used to initiate elongation [24]. For miRNA-specific RT, miRNA specific 
primers are used composed by a 3’-end complementary to the miRNA and a 5’-end 
that can either be a linear structure or a stem-loop [25]. Even though linear structures 
are simpler to design, stem-loop structures are usually more useful because they 
increase the specificity of the reaction, reduce annealing of the primer to the pre- and 
pri-miRNAs and avoid binding to double-stranded genomic DNA (dsDNA) molecules 
[26]. In cases with limited initial material or a large number of miRNAs to be analyzed, 
different approaches are recommended: miRNA universal RT, multiplex RT using a pool 
of stem-loop primers [27], or the addition of a cDNA pre-amplification step [28].  
qRT-PCR works by detecting the amount of fluorescent molecules, which directly 
correlates with the quantity of DNA present in the reaction [29]. Although several 
fluorescent technologies exist, SYBR Green and TaqMan hydrolysis probes are the 
most suitable methods for miRNA analyses. SYBR Green is an intercalating fluorescent 
dye that binds all dsDNA, even non-specific PCR products including primer-dimers [30]. 
These non-specific bindings limit accuracy of the detection method; hence the use of 
melting point analysis, also known as dissociation curve, is pivotal when using SYBR 
Green. Another option is hydrolysis probes which consist of a fluorescent reporter on 
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the 5’-end and a quencher on the 3’-end, which prevents emission of fluorescence by 
proximity.  During PCR, the probe and the primers anneal to the target sequence and 
the Taq polymerase extends the primer upstream of the probe. If the probe is bound 
to the correct target, the Taq polymerase hydrolyses the probe, resulting in increased 
fluorescence proportional to the amount of product generated [24]. 
 The reliability and reproducibility of the analyses can be improved using endogenous 
control genes, expression of which should remain as stable as possible in various 
tissues and conditions [25]. To date, there is no consensus on which endogenous 
control genes should be used when working with miRNA and, therefore, normalization 
is still rather empirical. Bioinformatic algorithms that identify adequate normalization 
gene [31] or small nucleolar genes such as U6 [32] may be used for this purpose. 
Recent qRT-PCR array methods combine high sensitivity provided by the stem-loop 
qRT-PCR with the ability to analyze a larger number of miRNAs in a single experiment 
[28]. qRT-PCR has been widely used to perform miRNA expression profiling using 
several array platforms developed in recent years. This technology is less time-
consuming than others such as microarrays and NGS, and the results do not require 
processing by biostatisticians.  
Yu et al. [33] investigated whether miRNA expression profiles were able to predict 
clinical outcome by analyzing 157 mature human miRNAs using a qRT-PCR array in 
fresh-frozen specimens from NSCLC patients. Cox regression analysis revealed a five-
miRNA signature that proved an independent predictor of cancer relapse and survival 
in both the testing set and an independent validation cohort. Another study analyzed 
differences in miRNA expression in bronchial carcinogenesis (four years duration). Sixty 
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biopsies obtained by fluorescence bronchoscopy were examined by qRT-PCR Low 
Density Array (LDA), capable of detecting 365 miRNAs. The authors found that most 
miRNA expression levels evolved in two steps during the carcinogenesis process: i) 
decrease in earliest stages of carcinogenesis, and then ii) increased when malignant 
transformation was engaged at stage of severe dysplasia [34]. Using the same qRT-PCR 
array technology, Silva et al. [35] determined the vesicle-related miRNA expression 
profile obtained from plasma samples of 28 NSCLC patients and 20 healthy controls. 
NSCLC patients and healthy controls differed with respect to vesicle-related miRNAs in 
plasma. In addition, NSCLC patients with low levels of miR-30e-3p and those with high 
levels of let-7f had worse survival. A LDA Panel including 756 probes was used by 
Berghmans et al. [36] in a prospective study in NSCLC patients treated with cisplatin 
and vinorelbine in first line. They assessed the predictive and prognostic value of 
miRNAs in 38 bronchial biopsies obtained in treatment naïve patients. A miRNA 
signature composed of miR-149 and miR-375 was found to be predictive of response, 
whereas a score including four miRNAs (miR-200c, miR-424, miR-29c and miR-124) was 
able to stratify patients according to prognosis.  
Hennessey et al. [37] examined expression of 180 miRNAs in serum of 30 treatment 
naïve NSCLC patients and 20 healthy controls by qRT-PCR assays (hydrolysis probe). 
They found that a combination of two differentially expressed miRNAs, miR-15b and 
miR-27b, was able to discriminate NSCLC patients from healthy controls with high 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) in the training and validation sets. However, the size of the analyzed cohorts was 
small and the findings require further validation. This year, Skrzypski et al. [38] have 
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published a study using microfluidic cards with TaqMan probes in order to assess 
expression of 667 miRNAs in 50 squamous cell carcinoma (SCC) patients who 
underwent curative surgery. In these patients, miRNAs with highest predictive value 
for distant relapse were analyzed in an independent cohort composed by 134 FFPE 
samples from SCC patients and also in 89 samples from adenocarcinomas (ADC) and 
normal parenchyma. They identified and confirmed the prognostic role of three novel 
miRNAs (miR-662, miR-192 and miR-192*) in operable SCC.  
Recently, Cazzoli et al. evaluated miRNAs isolated from plasma exosomes using a 724-
miRNA Ready-to-Use PCR Panel from Exiqon (Vedbaek, Denmark) [39]. MiRNAs were 
first assessed in a training set of 10 lung ADC, 10 lung granulomas and 10 healthy 
former smokers. Selected miRNAs were subsequently evaluated in a larger 
independent validation cohort (105 specimens: 50 lung adenocarcinomas, 30 lung 
granulomas, and 25 healthy smokers) by qRT-PCR. A four-miRNA signature (miR-378a, 
miR-379, miR-139-5p, and miR-200b-5p) was proposed to perform a screening test in 
lung cancer, and six miRNAs (miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-
100, and miR-154-3p) were selected for the diagnostic test to determine lung ADC.  
Microarrays and next generation sequencing (NGS) technologies are also used as 
screening tools because of their high throughput capacities (described below). 
However, results from these technologies need standardization and validation. qRT-
PCR has been widely used for this purpose, mainly due to its high sensitivity and 
specificity. For instance, Rosenfeld et al. [40] measured miRNA expression by 
microarray technology in 253 samples from different tumor tissues and metastases, 
developing a transparent classifier that differentiates tumors derived from different 
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tissue origins and therefore, could be useful for tracing unknown primary sources. This 
classifier was successfully validated by qRT-PCR in 65 blinded samples. Boeri et al. [41] 
also validated their results using this approach in both tissue and plasma samples. They 
suggested that qRT-PCR assessment of miRNAs in plasma will be a potentially useful 
and clinically applicable procedure to improve lung cancer management. Similarly, the 
University of Maryland (Baltimore, USA) group discovered two sets of miRNAs which 
could be employed in early detection of ADC (miR-21, miR-486, miR-375 and miR-
200b) [42] and SCC (miR-205, miR-210 and miR-708) [43] in sputum. Furthermore, they 
extended their research to plasma samples, where miRNAs were stably present and 
reliably measured. The authors were able to distinguish NSCLC patients from healthy 
controls with 86% sensitivity and 97% specificity [44]; however, it should be mentioned 
that the number of samples analyzed in these studies was small.  
A series of studies have analyzed expression of specific miRNAs selected for their 
potential function or predicted targets. In 2009, Gallardo et al. [14] reported the 
expression of miR-34 family members assessed in 70 NSCLC patients. They observed 
that miR-34 family members were downregulated in tumoral compared with normal 
tissue, and low levels of miR-34a expression correlated with high probability of relapse. 
They recently reported expression of miR-302-367cluster and miR-145, both related to 
transcription factors SRY-related HMG box 2 (SOX2) and octamer-binding transcription 
factor 4 (OCT4), in NSCLC patients. The group concluded that both miR-367 and miR-
145 are useful prognostic markers that may be used for risk stratification and selection 
of early NSCLC patients for adjuvant treatment [45]. Zhu et al. [46] analyzed gene 
expression levels of miR-183 family members, located on human chromosome 7 and 
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previously identified as potential oncogenes in several tumor types. The study was 
performed in 70 paired lung cancer samples (primary cancer, non-cancerous tissues 
and serum), as well as 44 serum samples from healthy volunteers and lung cancer cell 
lines. They demonstrated that high expression of tumor and serum miRNAs of the miR-
183 family were associated with overall poor survival in lung cancer patients. 
Similarly, Duncavage et al. [47] determined expression of six miRNAs (let-7a, miR-7, 
miR-21, miR-155, miR-210, and miR-221) with respect to recurrence in 46 surgically 
resected stage I NSCLC patients. Using FFPE tissue from both tumor and matched 
normal lung, they observed that down-regulation of miR-221 strongly correlated with 
recurrence in NSCLC. More recently, Chen et al. [48] analyzed expression of miRNA-17-
5p in 20 paired samples (lung cancer and adjacent normal tissues), and sera from 221 
lung cancer patients and 54 matched controls. They reported that miR-17-5p 
overexpression in serum correlated with reduced survival and may be an independent 
prognostic factor. In another recently published article, Zhang et al. [49] assessed 
expression of 20 miRNAs by qRT-PCR in plasma samples from 105 female ADC patients, 
observing that circulating levels of miR-195 and miR-122 are associated with prognosis 
and EGFR mutation status. Association between miRNAs and EGFR has previously been 
explored, especially the role of miRNAs in tyrosine kinase inhibitor-resistant NSCLCs.  
Garofalo et al. [50] found that miR-30b/c and miR-221/2 control the expression of 
genes involved in the apoptotic response and thus in sensitivity to gefitinib. Moreover, 
Romano et al. [51] reported that miR-494 induced down-regulation of BIM which is an 
important apoptosis regulator involved in drug resistance in NSCLC. Therefore, the 
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modulation of specific miRNAs may provide an approach to treatment of these 
patients. 
3.1.2. Microarray Platforms 
Microarrays platforms were among the first methods used in order to detect and 
quantify miRNAs. This technology, which allows the analysis of thousands of miRNAs in 
a single experiment, is based on the use of glass, quartz or nylon support platforms in 
which multiple probes are spotted or synthesized by photochemical synthesis [52,53]. 
Several aspects such as the short length of miRNAs, the existence of both mature 
miRNAs and their precursors, and melting temperature (Tm) differences, due to the 
variance in GC content, should be taken into consideration when performing miRNA 
microarrays [54,21]. To overcome these pitfalls, higher sensitivity and affinity probes 
have been developed. For example, locked nucleic acid (LNA) capture probes, which 
are able to increase the thermal stability of the duplex [55], or probes with 5'-end-
hairpin structure capable of avoiding hybridization to miRNA precursors [56]. 
Detection of miRNAs is usually performed using direct labelling with enzymatic 
reactions. For instance, T4 RNA ligase is widely used for the attachment of 
fluorophore-labeled nucleotides to mature miRNAs [56]. Microarray data must be 
normalized in order to eliminate background noise of the reaction and differences in 
the hybridization process which can be resolved using synthetic sRNAs or small nuclear 
ribonucleoproteins (snRNA) as a reference [57]. Furthermore, it is also important to 
validate the results obtained from microarrays with other technologies such as qPCR 
[21].  
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During the last decade, several studies using miRNA microarray have helped to 
elucidate the role of miRNAs in cancer-related processes. Moreover, some of these 
studies have been able to identify patterns which distinguish cancer patients from 
healthy controls, or classify patients according to clinical features and/or outcome. 
Volinia et al. [58] performed detailed large-scale miRNA profiles in 540 samples from 
six different cancer types, including lung, breast, stomach, prostate, colon, and 
pancreatic tumors. They identified a large portion of overexpressed miRNAs, some of 
which such as miR-17-5p, miR-20a, miR-21, miR-92, miR-106a, and miR-155, were 
already known to be associated with cancer 
In lung cancer, Yanaihara et al. [59] identified a unique profile which allowed the 
discrimination of lung carcinomas from normal lung tissues as well as distinguishing 
between different histology subtypes in a cohort of 104 patients. Among the different 
miRNAs composing the profile, high hsa-miR-155 expression significantly correlated 
with survival in lung ADC. The results were further validated by hybridization and qPCR 
in the same samples and also in an independent set of patients with ADC histology. In 
a cohort of 61 SCC samples, Raponi et al. [23] identified 15 miRNAs that were 
differentially expressed between normal lung tissue and SC; some of these miRNAs 
were found to have prognostic value, among them miR-155 and let-7 which were 
previously reported to be associated with poor prognosis in ADCs [59]. After 
performing a 752–miRNA microarray using specific and sensitive LNA probes, in 2010 
Patnaik et al. presented the widest analysis of lung cancer miRNAs until then. In FFPE 
samples from 77 stage I NSCLC patients, several miRNAs showed contrasting 
expressions between cases with and without recurrence [60]. More recently, the same 
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group reported differences in expression of 96 miRNAs in whole blood samples 
between ADCs and controls [61]. However, these results have not been independently 
validated thus far. 
In tissue and plasma samples from a spiral-CT lung cancer screening trial, Boeri et al. 
[41] found miRNA signatures which significantly distinguished tumors from normal 
tissues, tumor histology, growth rate, and clinical outcome. Furthermore, miRNA 
expression analyses in different groups of plasma samples (collected 1-2 years prior to 
disease onset, at the time of CT detection, and in disease-free smokers enrolled in the 
screening trial) resulted in miRNA signatures with strong predictive, diagnostic and 
prognostic potential. The authors emphasized the potential usefulness of detection in 
plasma in clinical practice due to the non-invasiveness of the technique. Using serum 
instead of plasma, Roth et al. [62] carried out blood-based microarray profiling of 
1158 different miRNAs using a microfluidic biochip in 21 NSCLC patients and 11 healthy 
individuals. In this work, they suggest that miR-361-3p and miR-625* might have a 
protective influence on the development of NSCLC, and therefore could be used as 
diagnostic tools. 
3.1.3. Next Generation Sequencing (NGS) 
Capillary electrophoresis (CE)-based Sanger sequencing, also known as “first-
generation sequencing”, has allowed scientists to study the genetic information of any 
biological system, including the human genome sequence. However, the limitations in 
throughput, scalability, speed, and resolution of this technology have led to the 
development of new sequencing methods, known as Next-Generation Sequencing 
(NGS). This is a group of methods that rely on template preparation, sequencing and 
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imaging, and thorough bioinformatic data analysis (reviewed by M. L. Metzker) [63]. 
This technology has several advantages such as identification and quantification of 
known miRNAs, as well as detection of novel miRNAs.  
The breakthrough came in 2005 when one of the first works using the sequencing-by-
synthesis method, developed by 454 Life Science, was published [64]. Since then, 
several NGS platforms have been developed; the most important of which are 
considered to be 454 (Roche Diagnostics, Basel, Switzerland), SOLiD (Life Technologies, 
Foster City, CA, USA) and Solexa (Illumina, San Diego, CA, USA). NGS techniques have 
been applied in miRNA studies in many species and they have become a powerful 
approach both for discovery and profiling of miRNAs. The NGS process starts with the 
construction of a cDNA-library of specific samples using PCR. In this step, platform-
specific adapters are ligated to the DNA products. The adaptors can be fixed to a solid 
phase in which the PCR takes place, such as in the Solexa platform, or to beads for 
emulsion PCR, as in the 454 and SOLiD platforms. After sequencing, bioinformatic 
analyses of the sequence reads are needed in order to identify known and novel 
miRNAs and for quantification of a given miRNA relative to the total reads in the 
sample [63]. 
NGS technologies also provide precise identification of miRNA sequences, permitting 
us to distinguish between miRNAs that differ by a single nucleotide and isomiRs 
(variants of the same miRNA) of varying length. One of the main limitations of this 
technology is the high cost, although these are decreasing with the development of 
new platforms and the use of DNA-barcodes which permit multiplexing of several 
samples in a single run [65]. Disadvantages are the need for a relatively large amount 
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of RNA and the complex bioinformatic analyses involved. Several attempts have been 
made to analyze the whole transcriptome sequence in lung cancer patients [66,67,68]. 
However, to date, few articles have been published analyzing miRNAs by NGS in lung 
cancer. In 2008, Chen et al. [69] studied the presence of miRNAs in serum and plasma 
of humans and animals employing a Solexa platform. They reported 63 miRNAs that 
were specifically detected in the serum of 11 lung cancer patients. Among these, miR-
25 and miR-123 were further validated by qRT-PCR in a set of 152 lung cancer patients 
and 75 healthy donors, although sensitivity and specificity of these assays were not 
reported.  
Solexa sequencing was also used by Hu et al. [70] to assess the prognostic impact of 
miRNA expression in human serum of NSCLC patients. They further validated miRNAs 
detected in serum by qRT-PCR in both a training and independent testing set of 
samples. The levels of four miRNAs (miR-486, miR-30d, miR-1 and miR-499) were 
significantly correlated with overall survival. Keller et al. [71] used SOLiD transcriptome 
sequencing for analysis of miRNAs in peripheral blood of 10 lung cancer patients and 
10 healthy controls. They developed a bioinformatic pipeline to generate miRNA 
profiles and detect novel miRNAs with prognostic and predictive information that 
could inform diagnosis. With this approach they detected 76 previously unknown 
miRNAs and 41 novel mature forms of known precursors, as well as 39 miRNAs 
significantly altered in cancer patients. Recently, a miRNA-sequencing (miRNA-Seq) 
study was conducted using SOLiD platform in ten fresh-frozen tumor samples from 
lung ADC patients [72]. The investigators found that miR-31 was up-regulated in 
patients with lymph node metastasis, compared with those without lymph node 
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metastasis. They validated the results by qRT-PCR and in an external validation cohort 
of 233 lung ADC cases from The Cancer Genome Atlas (TCGA) dataset. Furthermore, 
they carried out in vitro functional assays which showed that miR-31 increases cell 
migration, invasion, and proliferation in an ERK1/2 signaling-dependent manner. 
3.2. Analysis performed at single cell-level  
3.2.1. In situ hybridization 
In situ hybridization (ISH) is a technology based on the use of labeled probes for the 
detection of DNA and RNA directly in tissue samples which permits evaluation of 
expression in the different cells of the tumor microenvironment. There are two ways 
to visualize nucleic acids of interest in situ: fluorescent (FISH) and chromogenic (CISH) 
detection. Both use target-specific probes that hybridize with the sample, but the 
technology needed to visualize results is different for each method. While CISH permits 
to gain genetic information in the context of tissue morphology, FISH allows the 
possibility to assay multiple targets simultaneously and visualize them within a single 
specimen. This technology has been recently applied to the detection of miRNAs, due 
to the incorporation of LNA modified probes as has happened in other technologies 
such as qRT-PCR and microarrays. The miRNA probes can be obtained from Exiqon 
(Vedbaek, Denmark), which provides reporter nucleotides that form the basis of this 
technology. The most commonly used reporter nucleotides are biotin and digoxigenin, 
the latter being more suitable since it is not present in mammalian tissues and 
therefore avoids false positive results. These systems employ a conjugated alkaline-
phosphatase and the chromogen nitro blue tetrazolium (NBT) which, in the presence 
of 5-bromo-4-chloro-3-indolynitrolphosphate (BCIP), yields a purple-blue precipitate. 
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For the counterstaining, nuclear fast red is commonly used because it stains nuclei and 
is sufficient for analyzing cytoplasmatic signals [73].  
Two parameters are essential for the ISH process and must be accurately optimized: 
The extent of proteinase-K digestion (which depends on the concentration, incubation 
temperature and time) and the hybridization temperature which has been found to 
provide a fairly high signal-to-noise ratio at 30° C below the measured Tm [74]. As for 
other methodologies, negative and positive controls are pivotal. The negative control 
must be a sequence with no similarity to any human or mouse sequence, such as 
Scramble probes. U6 probes have been widely used as positive control for ISH itself. In 
addition, it would also be interesting to analyze expression of an abundant miRNA with 
cell-specific origin in order to control the methodology’s performance. For instance, 
miR-126 could be an adequate option because it is expressed in endothelial cells which 
are present in several types of tissues [75]. 
The major strength of the ISH methodology is that miRNA expression can be assessed 
specifically according to cellular compartment. As miRNA expression may have 
diverging prognostic impacts dependent on whether they are expressed in tumor cells 
or tumor stromal cells, it is essential to be able to localize the expression according to 
cellular compartments. Due to its novelty, to date, few attempts have been made to 
detect and analyze miRNA in lung cancer patients by ISH. The first study in reporting 
use of ISH in lung cancer samples was published by Voortman et al. [76] in 2010. The 
aim of this work was to determine if a panel of biologically relevant miRNAs could be 
used as prognostic or predictive biomarkers in the International Adjuvant Cancer Trial 
(IALT), one of the largest randomized studies of adjuvant chemotherapy in resected 
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NSCLC patients. For this purpose, they analyzed expression of seven miRNAs (miR-21, 
miR-29b, miR-34a/b/c, miR-155, and let-7) by qRT-PCR and ISH, the latter in selected 
cases. The results indicated that none of the seven miRNAs provided prognostic or 
predictive information about their cohort. The authors pointed out that the specimens, 
which were collected from a worldwide multicenter study, had not been gathered in 
accordance with standardized fixation and storage protocols. It seems that fixation and 
procurement variations affect the efficacy of ISH to a larger extent than miRNA 
isolation and qRT-PCR [77].  
To date, most publications on ISH detecting miRNAs in lung cancer have been 
published by the group of Bremnes and colleagues from Norway [78,79,80]. In 2011, 
they presented the first large-scale study combining high-throughput tissue-
microarrays (TMA) and ISH to evaluate the prognostic impact of miR-155 expression, 
which has frequently been reported as up-regulated in malignant cells. They found 
that high miR-155 expression was an independent negative prognostic factor in ADC 
and an independent favorable prognostic factor in SCC patients with regional nodal 
metastasis [79]. They further explored the correlation between miR-155 and several 
well-known angiogenic markers, finding that FGF2 was significantly associated with 
this miRNA [80]. Using the same cohort, they also evaluated the ISH expression of miR-
126 and its co-expression with VEGF-A by immunohistochemistry (IHC). MiR-126 is a 
key positive regulator that promotes angiogenesis in response to angiogenic growth 
factors, such as vascular endothelial growth factor-A (VEGFA). The analysis revealed 
that miR-126 is a strong independent negative prognostic factor in NSCLC, and its 
prognostic impact appears related to histology and nodal status [78]. Recently, miR-
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210 expression was also assessed in cancer and stromal cells of NSCLC patients and an 
association with improved disease-specific survival was observed (DSS) [81]. 
4. CONCLUSION 
Since a compelling body of evidence points to the direct involvement of miRNAs in 
carcinogenesis, several technologies have been developed with the aim of detecting 
and analyzing these molecules in different types of samples. Early on, the use of 
microarrays appeared as a great advanced to enhance the knowledge of the biological 
implications of miRNAs as well as opening the gate to new investigations regarding the 
possible use of miRNAs as biomarkers. Although microarray technology permits large-
scale studies, the comparability and accuracy of the derived data was not adequate 
and data validation was lacking. For this purpose, qRT-PCR has been widely used due 
to its high degree of accuracy. Moreover, new qRT-PCR arrays have been developed 
for large-scale miRNA profiling. One of the main limitations of both technologies is that 
only known miRNAs can be examined. NGS has solved this problem, and novel and 
known miRNAs can be identified in a single experiment. Although NGS is still an 
expensive method, current advances are leading towards new versions of the 
instruments which increase the analytical speed and lower the cost.  
Finally, a new miRNA detection technology, in situ hybridization, has emerged as an 
interesting option, mainly as it provides information about the exact localization of 
miRNAs. With this method, miRNAs can be specifically located within the tumor cell 
itself or within tumor stromal cells. As we have mentioned, several studies have 
already been published using the technologies previously described. A large amount of 
data is available on the potential use of miRNAs as diagnostic, prognostic and 
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predictive biomarkers. However, more studies are needed in order to validate, 
optimize and standardize procedures. This is pivotal for the future application of 
miRNAs as clinical tools for lung cancer diagnosis and management. 
5. FUTURE PRESPECTIVE 
It is expected that most relevant miRNAs, presumably miRNA-signatures, will be 
validated as diagnostic, prognostic and predictive biomarkers for clinical use in lung 
cancer patients in the near future. Since specificity and sensitivity will no longer be a 
problem, the aim will then be to improve technologies in terms of time and cost. In 
this regard, we expect that NGS platforms will become the gold standard for analyzing 
miRNAs since this technology is becoming faster and more affordable and yields a 
greater amount of data than other techniques. Furthermore, since the field of 
bioinformatics is also advancing rapidly, dealing with results obtained from NGS will 
become easier and more practical. However, in specific cases in which the location of 
miRNAs will need to be assessed, ISH will be probably remain the best approach; 
hopefully this technology will become better harmonized and standardized. In the 
future, it is also expected that tissue specimen collection will become more 
standardized, and importantly, liquid biopsies will emerge as powerful tools for the 
detection of distinct biological markers, including miRNAs. miRNAs detected in this 
type of biopsies are expected to provide a clearer picture of tumor evolution overtime 
and will address the problem of tumor heterogeneity. In summary, miRNA-profiling 
will become a potent tool in the near future for lung cancer diagnosis and prognosis, as 




MiRNAs in lung cancer 
 miRNAs are pivotal to the lung carcinogenesis process and present adequate 
characteristics to become biomarkers. 
 Several miRNA-signatures have been associated with diagnosis and prognosis in 
lung cancer using different methodologies. 
MiRNAs isolation and purification 
 It is pivotal to use an adequate RNA isolation method in order to obtain reliable 
miRNA-profiling results. 
MiRNA detection methods 
 Platforms based on microarray and qRT-PCR have been widely used in the last 
years in order to perform miRNA-profiling analysis. 
 NGS is becoming an important tool for miRNA analysis since it can detect 
known miRNA whilst also permitting discovery of new ones. 
 ISH permits identification of specific miRNAs and their exact location within the 
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ADC: Adenocarcinoma; DS: Discovery set; FFPE: Formalin-fixed, paraffin-embedded; ISH: In situ hybridization; NR: Not reported; 
NSCLC: Non-small cell lung cancer; OPS: Optimization set; OS: Overall survival; qRT-PCR: Quantitative reverse transcriptase PCR; RS: 
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Table 2. Available technologies for study of microRNAs. 
Methodology Main characteristics Advantages Disadvantages Companies 
qRT-PCR 
Gold standard for 
gene expression 
quantification 
For miRNA analysis, 
RNA has to be 





High sensitivity and 
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Requires a low 
input of RNA 
Less time-
consuming 
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of novel miRNAs 
Exiqon 
cDNA: Complementary DNA; qRT-PCR: Quantitative reverse transcriptase PCR; LNA: Locked nucleic acid 
Affymetrix (Santa Clara, CA, USA); Agilent Technologies (Santa Clara, CA, USA); Exiqon (Vedbaek, Denmark); 
Illumina (San Diego, CA, USA); Life Technologies (Foster City, CA, USA); Qiagen (Hilden, Germany); Roche 
Diagnostics  (Basel, Switzerland). 
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Table 3. Summary of most relevant miRNAs in lung cancer and their clinical implications. 
 
miRNA Expression in lung cancer Clinical correlation References 
miR-126 ↓ 
Distinguish between  NSCLC patients and 
healthy controls and it is an independent 
negative prognostic factor 
[41,42, 43, 44, 59,78] 
let-7 ↓ 
Distinguish between  NSCLC patients and 
healthy controls and it is associated with 
shortened survival 
[12, 23, 35, 47, 59] 
miR-21 ↑ Distinguish between  NSCLC or ADC patients and healthy controls [41, 42, 44, 58, 59] 
miR-210 ↑ 
Distinguish between SCC and healthy controls 
and it is associated with improved disease-
specific survival 
[23, 41, 43, 59, 81] 
miR-155 ↑ Distinguish between  NSCLC patients and healthy controls and it is associated with OS [23, 58, 59, 79] 
miR-221 ↑ Associated with aggressive NSCLC, with patients relapse and with resistance to TKIs [13,47, 50] 
miR-205 ↑ Distinguish between  NSCLC or SCC patients and healthy controls [43, 59, 69] 
miR-145  ↓ Associated with unfavourable prognosis in NSCLC [42, 45, 59] 
miR-34 ↓ 
Distinguish between SCC and healthy controls 
and it is associated with proliferation and 
relapse 
[11, 14] 
miR-31 ↑ Associated with ADC patients with lymph node metastasis [72] 
ADC: Adenocarcinoma; NSCLC: Non-small cell lung cancer; OS: Overall survival; SCC: Squamous cell carcinoma; 




Figure 1. MicroRNA (miRNA) biogenesis and mechanisms of action. In the nucleus, 
miRNA genes are transcribed by RNA Pol II into a long pri-miRNA transcript. Pri-miRNA 
is then processed by a complex that includes RNase III enzyme Drosha to form pre-
miRNA. This precursor is exported into the cytoplasm by Exportin 5, where it is further 
processed by DICER. A double-stranded miRNA of approximately 20 nucleotides is 
released and unwound by an helicase [6]. Mature miRNA is incorporated into the mi-
RISC complex, which binds to complementary sites in the mRNA target. Perfect 
complementarity of the binding leads to the cleavage of the target mRNA, whereas 
imperfect complementarity results in repression of the translational process [82]. 
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DGCR8: DiGeorge syndrome critical region gene 8; mi-RISC: miRNA-associated 
multiprotein RNA-induced silencing complex; ORF: Open reading frame; Pol II: 
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